RBC Capital Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $59
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
RBC Capital analyst Leonid Timashev maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and raises the price target from $48 to $59.
RBC Capital analyst Leonid Timashev maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and raises the price target from $48 to $59.